Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Ovarian cancer is the sixth most common malignancy among women in developed countries and the fifth leading cause of cancer-related death, representing a complex disease associated with poor survival rates.24 The combination chemotherapy of Paclitaxel (PTX) and Carboplatin (CARB) is considered the first-line treatment regimen for ovarian cancer.25 Both agents play distinct roles in inhibiting the growth of ovarian cancer through different mechanisms,26 and they are known to exert a synergistic anti-tumor effect by activating separate apoptotic signaling pathways, thereby potentially reducing drug resistance.25 The gonadotoxic effects of platinum-based chemotherapeutic agents have been demonstrated in numerous studies, both histopathologically and in terms of follicular development.27-29 In the present study, CARB administration led to significant histopathological damage in ovarian tissue, including follicular degeneration, prominent stromal edema, congestion, hemorrhage, inflammation, and fibrosis, particularly in the medullary region
Their ability to mimic or influence the action of larger bioactive molecules also makes them promising candidates for drug development and therapeutic applications
Combination approaches simultaneously address multiple bottlenecks, enabling faster overall progress through the repair cascade
Skin rashes or hives
10.3390/cancers15020548 15 CordaroM.CuzzocreaS.CrupiR
